中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體
Polyclonal Antibody to Inter Alpha-Globulin Inhibitor H4 (ITIH4)
IHRP; PK120; H4P; ITIHL1; Plasma Kallikrein-Sensitive Glycoprotein; Plasma kallikrein sensitive glycoprotein 120; Inter-alpha-trypsin inhibitor family heavy chain-related protein
- 編號PAH776Mu01
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 RPH776Mu01-中間α-球蛋白抑制因子H4(ITIH4)重組蛋白
- 緩沖液成份磷酸鹽緩沖液(pH7.4,含有0.02% NaN3和50%甘油)
- 性狀液體
- 濃度500μg/mL
- 且適物種Rattus norvegicus (Rat,大鼠)
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術,請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 648 ¥ 1512 ¥ 2160 ¥ 5400 ¥ 21600
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對ITIH4的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別ITIH4。
用法
Western blotting: 0.5-5μg/mL;
Immunohistochemistry: 5-50μg/mL;
Immunocytochemistry: 5-50μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當?shù)臈l件下存儲,損失率低于5%。
贈品
增值服務
相關產(chǎn)品
編號 | 適用物種:Mus musculus (Mouse,小鼠) | 應用(僅供研究使用,不用于臨床診斷!) |
RPH776Mu01 | 中間α-球蛋白抑制因子H4(ITIH4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPH776Mu02 | 中間α-球蛋白抑制因子H4(ITIH4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAH776Mu01 | 中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體 | WB; IHC; ICC; IP. |
PAH776Mu02 | 中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體 | WB; IHC; ICC; IP. |
SEH776Mu | 中間α-球蛋白抑制因子H4(ITIH4)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMH776Mu | 中間α-球蛋白抑制因子H4(ITIH4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSH776Mu01 | 中間α-球蛋白抑制因子H4(ITIH4)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻
雜志 | 參考文獻 |
Toxicology Letters | Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. [Pubmed: 23830989] |
International Journal of Medical Microbiology | Proteomic demonstration of the recurrent presence of inter-alpha-inhibitor H4 heavy-chain during aspergillosis induced in an animal model [Pubmed:24360996] |
Cancer Research and Treatment | Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma [pubmed:28724284] |
Diagnostics | Systemic Alterations of Immune Response-Related Proteins during Glaucoma Development in the Murine Model DBA/2J [Pubmed: 32585848] |
Liver Cancer | Biomarkers for locally advanced hepatocellular carcinoma patients treated with liver-directed combined radiotherapy [] |
留言咨詢